Table 2 Intervention, sedation monitoring, and study outcomes
Remimazolam (n = 30) | Propofol (n = 30) | P value | |
|---|---|---|---|
Intervention and sedation monitoring | |||
Study drug treatment | |||
Duration of infusion, h | 48.0 (21.5, 48.0) | 28.0 (23.5, 48.0) | 0.234 |
Infusion rate, mg/kg/h | 0.60 (0.45, 1.07) | 2.53 (1.94, 2.94) | – |
Infusion rate of remifentanil, μg/kg/h | 6.0 (6.0, 6.3) | 6.0 (5.7, 6.1) | 0.099 |
Received rescue sedation | 3 (10.0%) | 0 (0.0%) | 0.237 |
Received neuromuscular blockers | 12 (40.0%) | 7 (23.3%) | 0.165 |
Received norepinephrine | 21 (70.0%) | 24 (80.0%) | 0.371 |
Infusion rate, μg/kg/min | 0.06 (0.01, 0.19) | 0.07 (0.04, 0.31) | 0.148 |
Prone positioning | 12 (40.0%) | 7 (23.3%) | 0.165 |
RASS score | − 5.0 (− 5.0, − 4.0) | − 5.0 (− 5.0, − 4.0) | 0.717 |
Narcotrend Index value | 28.0 (21.0, 37.0) | 29.0 (21.0, 37.0) | 0.920 |
Primary outcome | |||
Percentage of time with a RASS score of -4 or -5 without rescue sedation, % | 100 (96.9, 100) | 100 (100, 100) | 0.168 |
Secondary outcomes | |||
Ventilator-free hours within 7 days, h | 0.0 (0.0, 34.1) | 0.0 (0.0, 3.3) | 0.256 |
Successful extubation | 13 (43.3%) | 7 (23.3%) | 0.100 |
Length of ICU stay, days | 23.5 (8.0, 28.0) | 28.0 (8.75, 28.0) | 0.841 |
28-day mortality | 11 (39.3%) | 17 (60.7%) | 0.121 |
Adverse events | |||
Hypotension | 16 (53.3%) | 18 (60.0%) | 0.602 |
Hypotension with intervention | 5 (16.7%) | 7 (23.3%) | 0.519 |
Bradycardia | 0 (0.0%) | 0 (0.0%) | – |